- Home
- KRRO vs XERS Comparison
KRRO vs XERS Comparison
Compare KRRO & XERS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KRRO
- XERS
- Stock Information
- Founded
- KRRO 2014
- XERS 2005
- Country
- KRRO United States
- XERS United States
- Employees
- KRRO N/A
- XERS N/A
- Industry
- KRRO Biotechnology: Pharmaceutical Preparations
- XERS Biotechnology: Pharmaceutical Preparations
- Sector
- KRRO Health Care
- XERS Health Care
- Exchange
- KRRO Nasdaq
- XERS Nasdaq
- Market Cap
- KRRO 490.1M
- XERS 500.2M
- IPO Year
- KRRO 2019
- XERS 2018
- Fundamental
- Price
- KRRO $37.61
- XERS $3.34
- Analyst Decision
- KRRO Strong Buy
- XERS Buy
- Analyst Count
- KRRO 7
- XERS 3
- Target Price
- KRRO $133.83
- XERS $4.87
- AVG Volume (30 Days)
- KRRO 91.5K
- XERS 1.3M
- Earning Date
- KRRO 11-12-2024
- XERS 03-05-2025
- Dividend Yield
- KRRO N/A
- XERS N/A
- EPS Growth
- KRRO N/A
- XERS N/A
- EPS
- KRRO N/A
- XERS N/A
- Revenue
- KRRO N/A
- XERS $187,361,000.00
- Revenue This Year
- KRRO N/A
- XERS $24.27
- Revenue Next Year
- KRRO N/A
- XERS $18.57
- P/E Ratio
- KRRO N/A
- XERS N/A
- Revenue Growth
- KRRO N/A
- XERS 22.72
- 52 Week Low
- KRRO $30.01
- XERS $1.69
- 52 Week High
- KRRO $98.00
- XERS $3.87
- Technical
- Relative Strength Index (RSI)
- KRRO 41.52
- XERS 49.66
- Support Level
- KRRO $36.02
- XERS $3.14
- Resistance Level
- KRRO $39.04
- XERS $3.60
- Average True Range (ATR)
- KRRO 3.11
- XERS 0.17
- MACD
- KRRO 0.18
- XERS -0.02
- Stochastic Oscillator
- KRRO 40.57
- XERS 37.74
About KRRO Korro Bio Inc.
Korro Bio Inc is a biopharmaceutical company with a mission to discover, develop, and commercialize a new class of genetic medicines based on editing RNA, enabling the treatment of both rare and highly prevalent diseases. It is generating a portfolio of differentiated programs that are designed to harness the body's natural RNA editing process to effect a precise yet transient single base edit. By editing RNA instead of DNA, Korro Bio is expanding the reach of genetic medicines by delivering additional precision and tunability.
About XERS Xeris Biopharma Holdings Inc.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.